Biogen Inc. or Grifols, S.A.: Who Manages SG&A Costs Better?

Biogen Inc. vs. Grifols, S.A.: A Decade of SG&A Management

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Biogen Inc. and Grifols, S.A. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Biogen's SG&A expenses have shown a steady increase, peaking in 2021 with a 38% rise from 2014 levels. In contrast, Grifols has maintained a more conservative growth in SG&A costs, with a 90% increase over the same period. This suggests that while Biogen invests heavily in administrative and sales functions, Grifols opts for a more restrained approach. The data highlights the strategic choices each company makes in balancing operational costs with growth ambitions. As the industry evolves, these strategies will play a pivotal role in shaping their financial health and market positioning.